

PART I: THE PHARMACEUTICAL PROCESS

Chapters 1 – 9

Chapter 1: FDA and Drug Approval Process

Megan Walter, Pharm.D. and CDR Lindsay Wagner, Pharm.D., BCPS

[1.1 Introduction](#)

[1.2 The New Drug Development Process](#)

[A. Discovery and Preclinical Research](#)

[B. Clinical Research](#)

[C. Investigational New Drug Application](#)

[D. Phases of Clinical Studies](#)

[E. Expanded Access Programs](#)

[F. Right to Try](#)

[1.3 New Drug and Therapeutic Biologic Application Process](#)

[A. New Drug Applications and Biologic License Applications](#)

[B. Fundamentals of NDA and BLA Submissions](#)

[C. NDA Classifications](#)

[1.4 FDA Review](#)

[A. Expedited Development and Review Programs](#)

[1. Accelerated Approval](#)

[2. Priority Review](#)

[3. Fast Track](#)

[4. Breakthrough Therapy](#)

[B. Labeling Review](#)

[1. Physician Labeling Rule \(PLR\)](#)

[2. Pregnancy and Lactation Labeling Rule \(PLLR\)](#)

[3. Additional FDA-Approved Patient Labeling](#)

[C. Risk Evaluation and Mitigation Strategies](#)

[D. Advisory Committee Meetings](#)

[1.5 The Generic Drug Approval Process](#)

[A. Abbreviated New Drug Applications](#)

[B. ANDA Approval](#)

[C. Generic Drug User Fee Amendments](#)

[1.6 Biosimilar Pathway](#)

[1.7 Over-the-Counter Drug Products](#)

[1.8 Postmarketing Surveillance](#)

[A. Adverse Event Reporting](#)

[B. FDA Adverse Event Reporting System](#)

[C. Post Marketing Requirements and Commitments](#)

[D. Sentinel Network](#)

[E. Drug Safety Oversight Board](#)

[1.9 Applicable Statutes and Implementing Regulations](#)

[A. Food and Drug Acts – 1906](#)

[B. Food, Drug and Cosmetic Act – 1938](#)

[C. Durham-Humphrey Amendment – 1951](#)

[D. Kefauver-Harris Amendment – 1962](#)

[E. Orphan Drug Act – 1983](#)

[F. Drug Price and Competition and Patent Term Restoration Act – 1984](#)

[1. Revision of New Drug Application Regulations - 1985](#)

[2. Revision of Investigational New Drug Application Regulations - 1987](#)

[3. Treatment Use of Investigational New Drugs - 1987](#)

[G. Prescription Drug User Fee Act \(PDUFA\) – 1992](#)

[H. FDA Modernization Act \(FDAMA\) – 1997](#)

[I. FDA Amendments Act \(FDAAA\) – 2007](#)

[J. Food and Drug Administration Safety and Innovation Act \(FDASIA\) – 2012](#)

[K. The Drug Quality and Security Act \(DQSA\) – 2013](#)

[L. 21st Century Cures Act – 2016](#)

[M. Food and Drug Administration Reauthorization Act \(FDARA\) – 2017](#)

[N. Coronavirus Aid, Relief, and Economic Security Act \(CARES Act\) – 2020](#)

[1.10 Conclusion](#)

[1.11 Glossary of Terms](#)

[References](#)

Chapter 2: The Front Lines of Clinical Research: The Industry and Ethical Considerations

Jonathan Young, Ph.D.

2.1 Introduction

2.2 Clinical Trial Service Providers

A. Food and Drug Administration

B. Clinical Trial Sponsor

C. Contract Research Organizations

D. Study Monitors

2.3 Clinical Trial Site

A. Site Management Organizations

B. Institutional Review Boards

2.4 The Evolution of Ethical Principles in Clinical Research

A. Respect for Persons

B. Beneficence

C. Justice

D. How the Investigator Applies Ethical Principles

2.5 Regulations Governing Institutional Review Boards

A. What Institutional Review Board Members Should Know about Clinical Research

B. What Institutional Review Board Members Should Know about Their Responsibilities

2.6 What the Site Should Know about Institutional Review Boards

A. What Research Requires Institutional Review Board Approval and Oversight

B. Requirements of an Investigator for Institutional Review Board Research Approval

2.7 Risks-vs.-Benefits Analysis: The Human Advocate

A. Identifying and Assessing the Risks

B. Minimal Risk vs. Greater-than-Minimal Risk

C. Vulnerable Populations and Minimal Risk

D. Determining Whether Risks Are Minimized

E. Assessing Anticipated Benefits

F. Determining Whether Risks Are Reasonable

G. Continuing Review and Monitoring of Data

2.8 Informed Consent: Not Just a Document

A. Elements of an Informed Consent

B. Additional Required Elements

2.9 Research Participants

2.10 Industry Trade Organizations and Support Services

2.11 Summary: Ethical Dilemmas in Clinical Research

References

Chapter 3: Search and Analysis of the Food and Drug Administration's FDA Adverse Event Reporting System (FAERS)

Paul N. Danese, Ph.D.

3.1 Introduction

3.2 Background

A. Small Clinical Trial Populations

B. Narrow Patient Demographics

C. Restricted Co-Administration of Medications

3.3 History of the FDA's Drug Safety Surveillance Systems

3.4 Submission of Adverse Event Reports to the FDA

A. Mandatory Reports

B. Voluntary Reports

3.5 Adverse Drug Reaction Information Captured by FAERS

3.6 Searching FAERS Data to Identify Possible Safety Problems

A. Statistical Methods to Identify Drug Safety Signals

B. Dechallenge and Rechallenge Data and Causality

C. Identifying Drug-Drug Interactions

D. Timelines and Deadlines of Adverse Event Reporting

3.7 The Food and Drug Administration's Use of FAERS in Regulatory Decisions

A. Boxed Warnings

B. Other Changes to a Medication's Prescribing Information

C. Determinations that No Action is needed and Continuing Investigations

3.8 Limitations of FAERS

A. Lack of Demonstration of Causality for Individual Reports

B. Extensive Under-reporting

C. Reporting Biases

D. Lack of Comparator Populations (Lack of a Denominator)

3.9 Search and Retrieval of Adverse Event Reports from the FDA's FAERS

A. Raw Data Files

B. FDA Public Dashboard

C. FOIA Requests

D. Commercial Vendors

3.10 Other FDA Adverse Event Reporting Systems

A. VAERS

B. MAUDE

C. Sentinel Initiative

3.11 Summary and Conclusions

References

Chapter 4: The Safety of Medicines: PharmacoVigilance, PharmacoSurveillance, PharmacoEmpowerment?

David Healy, M.D.

- 4.1 RxISK.org
 - 4.2 Antidepressants: Data Based or Evidence Based?
 - 4.3 Access to Adverse Event Data
 - 4.4 RCTs and Adverse Events // Ghost Writers
 - 4.5 RCTs & Primary Endpoints
 - 4.6 Post 1962: Confounding & Causality
 - 4.7 Pharmacovigilance
 - 4.8 RxISK.org and Pharmacovigilance 1.0
 - 4.9 Pharmacosurveillance
 - 4.10 TaperMD and Pharmacovigilance 2.0
 - 4.11 Summary and Conclusions
- References

Chapter 5: Important Code of Federal Regulations Applicable to Drug Product Liability Suits

S. Albert Edwards, Pharm.D., RAC, FRAPS

Chapter 6: The Regulation of Drug Product Information to Consumers

Frank J. Ascione, Pharm.D., MPH, PhD

- 6.1 The Historical Development of Food and Drug Administration (FDA)'s Regulatory Role
 - A. Early phase (prior to 1906): No significant government intervention
 - B. Early Regulatory Phase (1906-1938): Minimal Government Control
 - C. Greater Government Control (1938-1961)

- D. Debating Increased Consumer Access to Drug Product Information (1962-1983)
- E. Expanding Information Available to Consumers (1983-present)
- 6.2 Current State of Prescription Drug Product-Related Information Provided to Consumers
- 6.3 Evolution of Drug Advertising to US Consumers (DTCA)
 - A. Emergence of DTCA (1981-1982)
 - B. Voluntary Moratorium Period of DTCA (1983-1985)
 - C. Establishment of DTCA Regulations (1985–1999)
- 6.4 Current State of Direct-to-Consumer Advertising
 - A. Advantages and Disadvantages of DTCA
- 6.4 Summary and Conclusions
- References

Chapter 7: The Role of Investigative Journalism in Improving Drug Safety

Martha Rosenberg

- 7.1 Introduction
- 7.2 Direct-To-Consumer Advertising Increased with Covid
 - A. Unbranded DTC Advertising
 - B. Industry Funded Disease Awareness Groups
 - C. Encouraging Victim Politics
- 7.3 The Opioid Epidemic
 - A. Growing an Untapped Market
 - B. Aggressive Opioid Marketing
 - C. Fostering Opioid Addiction
 - D. Pill Mills and Addiction Medicine
 - E. Opioid Lawsuits Surface
 - F. Lack of Opioid Efficacy and Serious Side Effects
 - G. Paying for the Opioid Epidemic

7.4 Effective Hepatitis C Drugs Debut

- A. Lawmakers Investigate Hep C Prices
- B. Aggressive Hep C Marketing
- C. Screening as a Hep C Sales Tool
- D. Hepatitis C Safety Signals Emerge

7.5 Asthma Drug Safety Signals

- A. Xolair Leaves a Trail of Questions
- B. More Improper Xolair Marketing
- C. Safety Signals Surface with Xolair and a Lawsuit is Dismissed

7.6 Long-Acting Beta Agonists

- A. Glaxosmithkline Settlement included a Laba

7.7 Safety Questions About Leukotriene Receptor Antagonists

- A. Parents Report LTRA Side Effects
- B. LTRA Safety Signals Emerged Early
- C. Patients and Parents Fight Back
- D. Black Box Added to Singulair

7.8 Baldness Treatments Become Popular and Controversial

- A. Finasteride Side Effects Create Concern
- B. Medical Literature Confirms Finasteride Side Effects
- C. FDA Adds Warnings to Finasteride
- D. Finasteride User Speaks Out
- E. No Satisfying End for Finasteride Users

7.9 Biologic Drugs

- A. Tumor Necrosis Factor (Tnf) Blockers
- B. Tnf Blocker Risks

7.10 Other Popular Medications Come Under New Scrutiny

- A. N-Nitrosodimethylamine (NDMA
) Found in Medicines

1. Zantac Taken Off Shelves

2. NDMA Also Found in Metformin

7.11 Popular Stimulant Drugs Reveal Risks

A. Risks Seen with Modafinil

B. Fetal Risks Seen with Modafinil and Armodafinil

C. European Union Sues Provigil Makers

7.12 Fetal Risk Seen with NSAIDs

7.13 Bisphosphonates Continue to Present Risks

7.14 SSRI Antidepressants Linked to New Risks

A. SSRI Bone Thinning

B. SSRI Addictive Potential

7.15 Belviq, A Diet Drug Withdrawn from Market

7.16 Sleeping Pills Given Boxed Warnings

A. Public Figures on Sleeping Pills Make the News

B. Other Sleeping Pill Risks

7.17 Risks Associated with Fluoroquinolone Antibiotics

A. Fluoroquinolones Warnings Continue

B. Hormone Therapy Still Linked to Risks

C. Beware of Testosterone Marketing

D. New PPI Questions

References

Chapter 8: Evaluation of Causation in Drug Injury Cases

Donald H. Marks, M.D., Ph.D. and James T. O'Donnell, Pharm.D., M.S., FCP

8.1 What is Causation?

8.2 Importance of Establishing Causation

8.3 Definitions

8.4 Degree of Adverse Effects Relate to Intervention

8.5 Methodology to Investigate Causation

8.6 Structured Algorithms for Determination of Causation

A. Hill Criteria—Expanded Discussion

1. Strength of Association

2. Consistency of Results

3. Specificity

4. Temporal Relationship

5. Dose Response

6. Biological Plausibility

7. Biological Coherence

8. Experimentation

9. Analogy

8.7 Comments on the Individual Riddell Criteria for Causation,

8.8 Daubert and the Evolution of Causation,

8.9 Does Causation Need to be Established Before a Warning is Given?

8.10 What are the Qualifications needed to Give Expert Causation Opinions?

8.11 Case Reports Demonstrating Applications of Causation Principles

A. Case Report: Acyclovir Overdose – Pharmacist Recommended Overdose

B. Case Report: Challenging Cause of Death in a Malpractice Matter

C. Case Report: Determination of the Effects of Morphine in a Will Contest

D. Case Report: Proof of Drug-Induced Mental Changes in Complainant in Sexual Abuse Case

8.12 Summary and Conclusions

References

Chapter 9: General Principles of Pharmacology

James J. O'Donnell III, M.S., Ph.D., James T. O'Donnell, Pharm.D., M.S., FCP, and Vanessa Juettner, Ph.D.

9.1 Introduction

9.2 Basic Principles

A. Absorption

B. Lipid Diffusion

C. Determinants of Absorption

1. Lipid/aqueous partition coefficient and pH

2. Bioavailability

3. First pass effect

9.3 Routes of Administration

9.4 Extravascular Administration

A. Oral Administration

B. Rectal Administration

C. Other Routes of Administration

9.5 Intravascular Administration

9.6 Distribution

A. Diffusion

B. Volume of Distribution

C. Binding to Plasma Proteins and Cellular Constituents

D. Re-Distribution

E. Blood-Brain Barrier (BBB)

F. Placental Barrier

G. Therapeutic Range

H. Bioequivalence vs. Bioinequivalence

10.7 Drug Metabolism (Biotransformation)

A. Phase I Reactions

1. The families of human P450s

2. Induction of P450 enzymes

3. P450 Inhibition

B. Phase II Reactions

1. Metabolism of drugs to toxic products

9.8 Factors Affecting Drug Metabolism

- A. Disease
- B. Age
- C. Gender
- D. Genetic Factors

9.9 Drug Excretion

- A. Urinary Excretion
 - 1. Glomerular filtration
 - 2. Tubular secretion (active secretion)
 - 3. Tubular reabsorption
 - 4. Effects of pH on urinary excretion of ionizable drugs

9.10 Pharmacokinetics

- A. Introduction
- B. Therapeutic Window and Therapeutic Index
- C. Blood Levels for Narrow Therapeutic Index (NDI) Drugs
- D. Kinetic Modeling
- E. Drug Absorption and Elimination
 - 1. Absorption rate
 - 2. Elimination rate
 - 3. Clearance (CL)
 - 4. Area Under the Curve (AUC)
 - 5. Elimination (k)
 - 6. Elimination half-life
 - 7. Steady state
- F. Dosing
 - 1. Loading dose
 - 2. Maintenance doses (MD)
 - 3. Example—dosage adjustment in renal impairment
- G. Therapeutic Drug Monitoring (TDM)

H. Pharmacokinetics Summary

9.11 Drug Receptor and Pharmacodynamics

A. Agonists and Antagonists

B. Drug-Receptor Interactions

9.12 Dose Responses

A. Potency

B. Agonism and Antagonism

1. Partial agonists

9.13 Competitive Antagonism

9.14 Non-Competitive Antagonism

9.15 Summary and Conclusions

PART II: HIGH RISK DRUG THERAPIES RESULTING IN INJURY AND LITIGATION

Chapters 10 - 25

Chapter 10: Adverse Drug Reactions: Allergic Focus

James T. O'Donnell Pharm.D., M.S., FCP and James J. O'Donnell III, M.S., Ph.D.

10.1 Adverse Drug Reactions: How Large is the Problem? What Drugs are Involved? What are the Injuries?

A. Historical Perspective

B. Incidence of Adverse Drug Reactions

C. Food and Drug Administration Reporting Requirements

D. The "Seven Deadly Sins": Why Doctors Fail to Report Adverse Drug Reactions

E. Attitudes Toward Adverse Drug Reactions

F. Investigator Fraud

10.2 Classification of Adverse Drug Reactions

A. Categories of Adverse Drug Reactions

1. Type A reactions: Augmentation of the Pharmacological Response

2. Type B reactions: Bizarre (idiosyncratic)

10.3 Types of Drug Allergy and Hypersensitivity

A. The Nature of Drug Allergy

B. Dangerous Drug-Allergy Reactions

C. Drug Sensitivities Mimic Allergy Symptoms

D. Definitions of Allergic/Hypersensitivity Reactions

E. Idiosyncratic Reactions

F. Intolerance

G. Toxicity

H. Hypersensitivity Vasculitis

I. Predominantly Organ-Specific Reactions

J. Urticaria

K. Fixed Drug Eruptions

L. Photosensitivity Reactions

M. Generalized Exfoliative Dermatitis

N. Thrombocytopenia

O. Hemolytic Anemia

P. Agranulocytosis

Q. Treatment: Withdrawal of the Suspected Drug

R. Symptomatic Treatment

S. Prevention of Allergic Drug Reactions

T. Pseudoallergy

U. Angioedema

V. Hypersensitivity Reactions

10.4 Risk Factors, Drugs and Patients

A. Hypersensitivity Risk Factors

B. Identification of a Drug Allergy

C. Allergy to Antibiotics

D. Case Report: Cross-Allergenicity

10.5 Erythema Multiforme, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

A. Fixed Drug Eruptions

B. Erythema Multiforme-Like Eruptions

Case Report: Lamictal Induced Stevens Johnson Syndrome

C. Fluoroquinolones

E. NSAIDs Cross Reactivity Case Report

F. Radiographic Contrast Media

G. Local Anesthetics

H. Anticonvulsants (AED)

10.6 Summary and Conclusions

References

Chapter 11: Drug Induced Falls

James T. O'Donnell Pharm.D., M.S., FCP and James J. O'Donnell III, M.S., Ph.D.

11.1 Introduction

11.2 The Definition of Fall

11.3 Epidemiology

11.4 Causes and Risk Factors

A. Physiological Risk Factors for Falls in the Elderly

B. Psychological Risk Factors

C. Medical Conditions

11.5 Medication-related Falls

11.6 Types of Medications that Increase the Risk of Fall

A. Centrally Active Medications

B. Benzodiazepines

C. Antipsychotics

D. Antihypertensives

1. Orthostatic Hypertension and Risk of Fall

E. Opioids

11.7 Marijuana

11.8 Alcohol

11.9 Hip Fractures

11.10 Polypharmacy

11.11 Fall Risk Assessment

11.12 Types of Assessments

11.13 Strategies for Fall Prevention in Institutionalized Settings

A. Screening

B. Addressing Risk Factors

1. Monitoring Patients

2. Environmental Interventions

3. Educational Programs

4. Reducing Fall Injury

C. Discharge Planning

D. Disseminating Evidence: Awareness and Intervention Work!

11.14 Summary and Conclusions

References

Chapter 12: Drug Induced Movement Disorders

Jadwiga Najib, B.S. Pharm.D., BCPS, and Meagan Bailey, M.D.

12.1 Introduction

12.2 Presentation

12.3 Agents Associated with Drug-Induced Movement Disorders

12.4 Risk Factors

12.5 Sequelae of Drug-Induced Movement Disorders

12.6 Theories of Causation

12.7 Drug-Induced Movement Disorders in Children and Adolescents

12.8 Drug-Induced Movement Disorders in the Elderly

12.9 Acute/Intermediate Drug-Induced Movement Disorders

A. Dystonia

1. Presentation

2. Implicated agents

3. Risks

4. Management

B. Ataxia

C. Bruxism

D. Neuroleptic Malignant Syndrome

E. Serotonin Syndrome

12.10 Chronic Drug-Induced Movement Disorders

A. Akathisia

1. Presentation

2. Case study: Trazodone-induced akathisia

3. Implicated agents

4. Other drugs

5. Risks

6. Management

B. Parkinsonism

1. Presentation

2. Case Study: Neuroleptic-Induced Parkinsonism

3. Implicated agents

4. Other drugs

5. Risks

6. Management

C. Myoclonus, Tremor, Tics, Asterixis

12.11 Persistent/Tardive Drug-Induced Movement Disorders

A. Tardive Dyskinesia

1. Presentation

2. Case Study: Neuroleptic induced oral buccal dyskinesia and akathisia

3. Implicated agents

4. Case Study: Metoclopramide induced oral buccal lingual dyskinesia

5. Risks

6. Management

B. Tardive Akathisia

C. Tardive Dystonia

1. Case Report: Neuroleptic induced cervical dystonia

D. Other Tardive Variants

12.12 Drugs Used for Movement Disorders

12.13 Monitoring

12.14 Clinical and Legal Issues in Psychiatry

12.15 Summary and Conclusions

References

Chapter 13: Acute Adverse Drug Events in Critical Care Emergency Department and Intensive Care Units

Gourang P. Patel, Pharm.D., M.Sc., BCPS, BCCCP, FCCM

13.1 Background

A. Epidemiology

B. Environment

13.2 High-Risk Medication-Related Events

A. Hypersensitivity Reactions

B. Cardiovascular Reactions

1. Blood pressure (BP)

2. Heart rate (HR)

3. Arrhythmias

C. Nephrotoxicity

1. Aminoglycosides

2. Amphotericin B

3. Intravenous contrast

D. Hypoglycemic Events

E. Infusion-Related Reactions

1. Extravasations

2. Propofol-related infusion syndrome (PRIS)

3. Intravenous N-acetylcysteine (NAC)

F. Reversal Agents

1. Protamine

2. Vitamin K

3. Naloxone

4. Flumazenil

13.3 Summary and Conclusions

References

Chapter 14: Nephrotoxic Drugs

Jason M. Kidd MD, Domenic A. Sica, M.D. and Todd W. B. Gehr, M.D.

- 14.1 Introduction
- 14.2 Framework of the problem
- 14.3 Basis for the kidney being susceptible to damage
- 14.4 Patient groups most susceptible to nephrotoxicity
- 14.5 Demographics of chronic kidney disease
- 14.6 Methods to assess renal function and/or damage
- 14.7 Level of renal function at which drug accumulation occurs
- 14.8 Nephrotoxic drugs
 - A. What constitutes prompt clinical action in the face of nephrotoxicity?
- 14.9 Nephrotoxicity scenarios
 - A. Lithium toxicity
 - B. Gentamicin toxicity
 - C. Dialysis-related issues
 - D. Drug Clearance in Relationship to Renal Failure
 - 1. Case 1
 - 2. Case 2
 - E. Angioedema with an ACE inhibitor
 - F. Fatal hyperkalemia with medications
 - G. Statin therapy and the development of myopathy
 - H. Nephrotoxicity related to checkpoint inhibitor use
- 14.10 Summary and Conclusions
- References

Chapter 15: Drug Induced Liver Disease

James T. O'Donnell, Pharm.D., M.S., FCP, James J. O'Donnell III, M.S., Ph.D., Donald H. Marks, M.D., Ph.D., Paul Danese, Ph.D.

15.1 Introduction: The Problem of Drug-Induced Liver Disease

15.2 History of Adverse Drug Reactions

15.3 Overview of DILD, Epidemiology Risk Factors, Histopathology, and Diagnoses

A. Epidemiology of Drug Hepatotoxicity

B. Risk Factors

C. Histopathology

D. Diagnosis

15.4 Hepatic Drug Metabolism

15.5 FDA and DILD

15.6 Types of Liver Injury

A. Hepatitis

B. Massive Hepatic Necrosis (Fulminant Hepatitis)

C. Drug-induced Vanishing Bile Duct Syndrome

15.7 Specific DILD Product Areas and Case Discussions

A. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Use and Hepatotoxicity

B. Isoniazid-Induced Hepatotoxicity

C. Acetaminophen

1. Acetaminophen Toxicity Assessment Nomograms

2. FDA Report - Acetaminophen Induced Liver Disease

D. Macrolide Hepatotoxicity

E. Methotrexate (MTX) Hepatotoxicity

F. Estrogens and Oral Contraceptive Steroids

G. Statins

H. Ticlopidine

I. ACE Inhibitors and AT II Receptor Antagonists

J. Fluoroquinolones

K. Terbinafine

L. Ketoconazole

M. Selective Serotonin Reuptake Inhibitors – Serzone Liver Toxicity

N. Herbal and Other Dietary Supplements and Hepatotoxicity

15.8 Summary and Conclusions

References

Chapter 16: Antineoplastic Therapy

Kathryn Schultz, Pharm.D. and Eris Tollkuci, Pharm.D.

16.1 Background

16.2 Chemotherapy - Antimetabolites

16.3 Chemotherapy - Antimicrotubules

16.4 Chemotherapy - Alkylators

16.5 Chemotherapy - Topoisomerase I Inhibitors

16.6 Chemotherapy - Topoisomerase II Inhibitors

16.7 Chemotherapy - Antitumor Antibiotics

16.8 Chemotherapy - Miscellaneous

16.9 Targeted Therapy

A. Infusion-related reactions (IRRs)

B. Immunotherapy (Immune Checkpoint Inhibitors)

1. Infusion-related reactions

2. Immune-Related Adverse Events (irAEs)

16.10 Tumor Lysis Syndrome

16.11 Hepatotoxicity

16.12 Summary and Conclusions

References

Chapter 17: Dangers of Opioids

Jennifer Splawski, M.S., Pharm.D., BCPS, James T. O'Donnell, M.S., Pharm.D., James J. O'Donnell III, M.S., Ph.D.

17.1 Introduction

A. Definitions

B. History

17.2 Pharmacology of Opioids

A. Effects

B. Opioid Neural Receptors

1. Central Nervous System (CNS) Receptors

2. Peripheral Nervous System (PNS) Receptors

C. Routes of Administration

1. Oral

2. Intramuscular

3. Subcutaneous

4. Intravenous

5. Transdermal

6. Sublingual and Buccal

7. Neuraxial

D. Metabolism

E. Excretion

17.3 Toxicity of Opioids

A. Respiratory Depression

B. Symptoms of Overdose

17.4 Epidemiology of Opioid Abuse

A. Opioid Abuse in Adolescents and Young Adults

B. Opioids in Pregnancy

17.5 Contributions to the Opioid Epidemic

A. Opiates Handed Out Like Candy to 'Doped-up' Veterans

B. United States Reaches \$22 Million Settlement Agreement with CVS For Unlawful Distribution of Controlled Substances

C. Former Walmart Pharmacists Say Company Ignored Red Flags as Opioid Sales Boomed

D. Federal Judge Approves Landmark \$8.3 Billion Purdue Pharma Opioid Settlement

17.6 Combatting the Opioid Epidemic

A. Prescription Monitoring Programs (PDMP)

B. Naloxone Dispensing

C. Medication for Opioid Use Disorder (MOUD)

1. Buprenorphine

A. Pharmacokinetics

B. Adverse Effects

C. Place in therapy

1. Methadone

A. Pharmacokinetics

B. Equianalgesic Dosing

C. Drug Interactions

D. Cardiovascular Effects

E. Consequences of Ignorance of Proper Dosing of Methadone

F. Methadone Legal Case Examples Involving Patient Demise

G. Applying Lessons Learned and Action for Institutional Committees

17.7 Case Reports: Opioid Toxicity Causing Respiratory Arrest, Brain Damage, and Death

A. Case Report: Respiratory Arrest and Brain Damage Following Morphine Overdose

B. Case Report: Fentanyl Epidural Respiratory Arrest

C. Case Report: Fentanyl (Duragesic®) Death in Discharged Patient

D. Case Report: High Dose Fentanyl Patch Prescribed in Opiate-Naïve Patient—Death

E. Case Report: Heroin and Other Opioids

F. Case Report: Hydromorphone (Dilaudid®) Respiratory Arrest

17.8 Investigation and Prosecution of Pain Clinics by the Department of Justice (DOJ)

17.9 Summary and Conclusions

References

Chapter 18: Adverse Effects of Diabetic Drugs: Focus on Hypoglycemia

Gourang P. Patel, BS Chem, PharmD, MSc, BCPS and James T. O'Donnell, Pharm.D., M.S., FCP, ABCP, FACN

18.1 Diabetes Demographics and Epidemiology

18.2 Insulin

18.3 Insulin Preparations

18.4 Clinical Use of Insulin

A. Dosing

18.5 Hypoglycemia (Low Blood Sugar)

A. Etiologies of hypoglycemia

B. Insulin-induced hypoglycemia

C. Deaths by Hypoglycemia

18.6 Pathophysiology and Clinical Symptoms of Hypoglycemia

18.7 Incidence

18.8 Pathophysiology and Biochemistry of Hypoglycemia

18.9 Adverse Reactions Involving Hypoglycemia

A. Insulin damages baby's brain; pharmacist error suggested

18.10 End Product Testing Recommended

18.11 Insulin Murders

18.12 Hypoglycemia from the Sulfonylurea Derivatives

18.13 Adverse Effects of the Sulfonylureas

18.14 Drug Interactions with Sulfonylureas

18.15 The Gliptin Class New drugs for Diabetes Treatment Type 2 Diabetes

18.16 Thiazolidinediones

A. Hepatic Failure

B. Bladder Cancer

18.18 Summary and Conclusions

References

Chapter 19: Parenteral Nutrition Related Errors and Complications

Erica M. Fernandez, Pharm.D., BCCCP, BCPS

19.1 Introduction

19.2. Basic principles of PN

19.3 PN Provision Categories

A. Prescribing

B. Transcribing and Verification

C. Compounding

D. Administration

19.4. Monitoring and Complications

A. Glycemic Control

B. Refeeding Syndrome

C. Hepatobiliary Complications

D. Complications involving micronutrients

19.5 PN Component Shortages and Adverse Events

19.6 Summary and Conclusion

References

Chapter 20: Antidepressants: Clinical Use and Litigation

Henry Cohen, Pharm.D., M.Sc., FCCM, BCPP, BCGP and Michael Liu, Pharm.D., MBA, BCCCP, BCNSP, BCPS

20.1 Major Depressive Disorders

20.2 Antidepressant Pharmacology

20.3 Antidepressant Overdose

A. Trazodone and Permanent Neurologic Sequelae

20.4 Antidepressants and the Patient with Suicidal Ideation

A. Prozac and Suicidal Ideation

1. Woulfe v. Eli Lilly & Co.
2. Espinoza v. Eli Lilly & Co.
3. Cassidy v. Eli Lilly & Co

B. Paxil and Suicidal Ideation

1. Dolin v. GlaxoSmithKline

C. Antidepressant and Increased Suicidality in Pediatrics

1. Schilf v. Eli Lilly & Co.

20.5 Broken Heart Syndrome: Tako Tsubo Cardiomyopathy Associated with Use of Antidepressants

20.6 The Adverse Effects of Antidepressants and the Duty to Warn

A. Docken v. Ciba-Geigy

B. Stebbins v. Concord Wrigley Drugs, Inc. et al.

C. Morgan et al. v. Wal-Mart Stores, Inc.

D. Kampmann v. Mason

E. Cottam v. CVS

20.7 Antidepressants and Alcohol

A. Kirk v. Michael Reese Hospital

B. Hand v. Krakowski

20.8 Selective Serotonin Reuptake Inhibitors and the Serotonin Syndrome

20.9 Hepatic Cytochrome P450 Drug Interactions and Cyclic Antidepressants

20.10 Antidepressants and Herbal Agents Drug Interactions

20.11 Serzone and Liver Disease

20.12 High Blood Pressure Associated with Venlafaxine Use

20.13 SSRI use and Birth Defects

20.14 Bupropion XL and Seizures

20.15 The Pharmacist's Role

20.16 The Omnibus Budget Reconciliation Act

20.17 How Safe is it to Buy Prescription Medications Over the Internet?

20.18 In a Perfect World

20.19 Summary and Conclusions

References

Chapter 21: Contrast Media Neurotoxicity Following Myelography

Stephanie E. Tedford, Ph.D., and James T. O'Donnell, Pharm.D., M.S., FCP

21.1 Introduction

21.2 Case Reports

A. Case I Intrathecal Iopamidol

B. Case II Intrathecal Iothalamate

21.3 Discussion

A. Mechanisms for cerebral (neurotoxic) injury

B. Contrast-induced neurological and cognitive deficits

C. Contrast-induced visual and auditory impairment: Further evidence for cerebral insult to cortical brain structures

21.4 Summary and Conclusions

References

Chapter 22: Fetal Drug Exposure

Damani Parran, Ph.D., MBA, DABT, James T. O'Donnell, Pharm.D., M.S., FCP, ABCP, FACN, James J. O'Donnell III, M.S., Ph.D.

22.1 Introduction

22.2 Critical Periods of Human Development and Susceptibility

22.3 Special Considerations of Drug Exposure during Pregnancy

22.4 Historical Human Developmental Toxicants

A. Thalidomide

B. Ethanol

C. Diethylstilbestrol

D. Retinoids

E. Cocaine

22.5 Developmental Toxicity of Prescription Drugs

A. Valproic Acid

B. Phenytoin

C. Warfarin

D. Benzodiazepines

22.6 Additional Prenatal Environmental Influences

A. Malnutrition

B. Poverty

C. Emotional State

D. Mother's Age

E. Infections and Diseases

22.7 FDA Pregnancy Categories for Prescription Drug Labeling; Final Rule

22.8 Analyses of Litigated Cases Alleging Fetal Drug Injury

A. Effects of Methadone and Smoking on the Fetus

B. Effects of Lisinopril on Fetus – Defense of Causation

22.9 Summary and Conclusions

References

Chapter 23: Geriatric Medication Misadventures

Rodney G. Richmond, M.S., Pharm.D., BCGP, FASCP and James C. Norris, Ph.D., DABT, ERT

23.1 Introduction

A. Outpatient Medication Use

B. Hospital Medication Use

- C. Long-Term Care Medication Use
- 23.2 Altered Clinical Response to Drugs
 - A. Pharmacokinetics
 - B. Pharmacodynamics
- 23.3 Preventable Drug-Related Problems
 - A. Polypharmacy
 - B. Transitions of Care
 - C. Inadequate Monitoring
 - D. Potentially Inappropriate Medication Use
- 23.4 Legal Cases Application
- 23.5 Summary and Conclusions
- References

Chapter 24: Medication Errors

James T. O'Donnell, Pharm.D., M.S., FCP, ABCP, FACN, R.Ph. and James J. O'Donnell III, M.S., Ph.D.

- 24.1 History and Overview
- 24.2 Medication Errors in Epidemic Proportions
- 24.3 Types of Medication Errors
 - A. Enhancing Healthcare Team Outcomes
 - B. Improving Reporting of Medication Errors
- 24.4 Medication Use Process
- 24.5 System Errors
- 24.6 Which Drugs are Most Often Involved in Medication Errors?
- 24.7 Prevalence of Medication Errors
- 24.8 Vaccine Errors
- 24.9 How has Modern Research Improved Therapeutics and Reduced Drug-Related Morbidity?
Pharmacogenomics

24.10 Systems for Medical Error Prevention

- A. Electronic Prescribing (E-prescribing)
- B. When Electronic Prescribing is Unavailable
- C. Effective Drug Monitoring Systems
- D. The Importance of Continuing Education
- E. Reporting All Adverse Drug Events

24.11 Summary and Conclusions

References

Chapter 25: Anticoagulants: Therapeutics, Risks, And Toxicities

James T. O'Donnell, Pharm.D., M.S., FCP, ABCP, FACN, James J. O'Donnell III, M.S., Ph.D., Stephanie E. Tedford, Ph.D.

25.1 Introduction

25.2 Summary of Anticoagulant Therapy

- A. Definition
- B. Use
 - 1. Treatment of coronary heart disease
 - 2. Warfarin and dabigatran
 - 3. Treatment of thrombogenesis

25.3 Limitations of Current Therapy

- A. Heparin
- B. Low Molecular Weight Heparin (LMWH)
- C. Heparin-Induced Thrombocytopenia (HIT)
 - 1. Pathogenesis of the autoimmune response
 - 2. Pathogenesis of the prothrombotic state
 - 3. Clinical presentation of HIT
 - 4. Diagnosis

- a. Dismissing HIT
- b. Diagnosing HIT
- 2. Two Approaches: class and titer

5. Treatment of HIT

- a. Fondaparinux
- b. Re-exposure to heparin

6. Conclusion HIT and HITT

D. Warfarin

25.4 Monitoring Warfarin Oral Anticoagulation

25.5 Alternatives to Warfarin - DOACs

A. Pradaxa (Dabigatran) vs. Warfarin

B. Direct Oral Anticoagulation (DOAC) Therapies

C. DOAC reversal agents

D. Antiplatelet Therapy

25.6 Summary and Conclusions

References

Part III: PHARMACISTS, PHARMACY AND PHARMACY PRACTICE

Chapters 26 - 33

Chapter 26: Pharmacy Practice, Managed Care, And Manufacturers

F. Randy Vogenberg R.Ph., Ph.D. and Rita Marcoux R.Ph., MBA

26.1 Introduction to Pharmacy and the Related Managed Health Care Environment

26.2 Pharmacists as Health Care Professionals: Training, Support Staff, and Life-long Learning

A. Registration, Certifications, Credentialing, Colleges Of Pharmacy, And Accreditation Matters For Pharmacy Professional Staff

26.3 Practice Sites: Inpatient, Ambulatory/Community, Specialty, Long Term Care, and Other (compounding, nuclear)

A. Practice settings, Practice site Certification, Pharmacist practice versus the Business of pharmacy, Credentialing, and Accreditation matters

26.4 Issues for Pharmacy Practice, Insurance, and Managed Care In the Near Future

A. The landscape of Practice Sites and Changing Business of Health Landscape

26.5 Current and Near Future Issues for Pharmacists

A. Landscape of Pharmacy Practice, The Changing Professional Marketplace

26.6 Pharmaceutical Manufacturer Through Wholesaler and Distribution Supply Chain

26.7 Manufacturers: Traditional and Innovative Segments

A. Non-Biologic Medications

B. ResearchIntensive, Biologics, Gene, and Generic Segments

1. Biologic Medications

26.8 Pharmaceutical Manufacturer Customers

A. Organization and Operations

B. Other Targeted Customer and Class of Trade Segments

C. Contracting and Change in the Pharmaceutical Industry

26.9 Health Care Industry Changes in the Near Future

26.10 Summary and Conclusions

References

Chapter 27: The Pharmacist's Utilization of the National Patient Safety Goals to Contribute to Safe and Effective Medication Use

Jennifer Splawski, Pharm.D., MS, BCPS and Heather Minger, Pharm.D., BCPS

27.1 Introduction

A. Overview of 'The Goals'

27.2 Goal 3 and the Pharmacist's Role

A. NPSG.03.05.01 relating to Anticoagulation

1. Introduction

2. Warfarin Overview
3. Patient monitoring
4. Patient Education
5. Direct Oral Anticoagulant
6. Anticoagulation Reversal Overview
7. Anticoagulation Reversal Programs
8. Patient Education
- B. NPSG.03.06.01 relating to Reconciling Medication Information

1. Introduction
 2. The Process of Medication Reconciliation
 3. Improved Accuracy
 4. Decreased Mortality
 5. Allergy Identification
 6. Discharge Medication Reconciliation
 7. Utilization of the Pharmacist Extenders in Medication Reconciliation
- 27.3 Summary and Conclusions

References

Chapter 28: Pharmacist Malpractice and Liability

James T. O'Donnell, Pharm.D., M.S., FCP, ABCP, FACN and James J. O'Donnell III, M.S., Ph.D.

28.1 Introduction

28.2 The Science of Risk Management

28.3 Claims Studies

The Pharmacists Mutual Claims Study

CNA Claims Study (CNA/HPSO)

A. CNA Database and Methodology

B. Most Common Categories of Errors

C. Claim Analysis by Insurance Source & Licensure Type: Pharmacists v. Technicians

- D. Factors Affecting Wrong Drug Dispensing Errors
 - E. Drugs Involved in Claims
 - F. Most Common Error: Wrong Drug
 - G. Wrong Drug Strength
 - H. Wrong Directions
 - I. Wrong Route of Administration
 - J. Lack of Drug Review
 - K. Counseling: A Powerful Weapon Against Liability
 - L. Non-Bodily Injury
 - M. Miscellaneous Errors
 - N. Wrong Directions
 - O. Lack of Drug Review
 - P. Avoiding Errors and Malpractice
- 28.4 Specific Pharmacist Malpractice Case Reports / Topics
- A. Duty to Warn?
 - B. Wrong Drug
 - C. Quotas and Metrics: Contributing to the Problem?
 - D. Controlled Substances Violations by Pharmacists
 - E. Methotrexate (MTX) errors
- 28.5 Pharmacists Need to do the Right Thing
- 28.6 Steps Toward a Better Outcome
- 28.7 Summary and Conclusions
- References

Chapter 29: Regulation of Pharmacy Practice

Ned Milenkovich, Pharm.D., J.D.

29.1 Introduction

29.2 Licensure of Professional Activities

- A. Boards of Pharmacy – A Closer Look
- B. National Association of Boards of Pharmacy

29.3 Practice Standards

- A. Legally Circumscribing Pharmacy Practice

29.4 Licensure Process to Practice Pharmacy

- A. Licensing
- B. Licensing of Pharmacists

29.5 The Different Types of Pharmacy Licenses

- A. Disciplinary Actions
- B. Causes of Disciplinary Action
- C. Practice Focus on Licensure
- D. Ongoing Professional Education
- E. Support Personnel

29.6 Federal Drug Laws

- A. Obra '90
- B. Medicare
- C. Medicare Part D
- D. Medicaid
- E. Prescription Drug Coverage
- F. Fraud, Waste and Abuse
- G. 340b Drugs
- H. Pharmacy Compounding
- I. FDA Rems
- J. DEA

29.7 Pharmacy Practice: Putting it Together

- A. Pharmacy Practice: An Ongoing Progression
- B. Collaborative Practice Agreements
- C. Drug Utilization Review (DUR)

- D. Other Mandates Impacting Pharmacy Practice Quality Assurance Regulations
- E. Health Insurance Portability and Accountability Act Of 1996, As Amended

Chapter 30: Emergency Department Pharmacist

Victor Cohen, B.S., Pharm.D., BCPS, CGP, Samantha P. Jellinek-Cohen, Pharm.D., BCPS, CGP, Megan Musselman Pharm.D., M.S., BCPS, BCCP

30.1 Introduction

30.2 Epidemiology of Drug Injury and Contributing Risk Factors

A. Contributing Risk Factors

30.3. Etiology and Sources of Drug Injury in the ED

30.4 Clinical Pharmacy in the ED: A Historical Perspective

30.5 The ED Pharmacist Plays a Dual Role at Maimonides Medical Center

30.6 The ED Pharmacist: A Sub-specialist in Emergency Medicine

A. Training and Education

B. Certification

30.7 The ED Pharmacist as a Generalist

30.8 The ED Pharmacist Ensuring Optimal Continuum of Care

A. The ED and Infectious Diseases

B. The ED Pharmacist and the Ambulatory Care Interphase

C. The ED Pharmacist and Transitions of Care (TOC)

1. Medication admission notes in the ED

D. The ED Pharmacist as a Clinical Toxicology Consultant

E. The ED Pharmacist and the Cardiology Interface

F. The ED Pharmacist and Neurological Emergencies

G. The ED Pharmacist and Pulmonary Emergencies

H. The ED Pharmacist and Public Health Services in the ED

30.9 Building Layers of Defense Against Drug Injury

- A. Detecting and Preventing Drug Injury in the ED
- B. The ED Pharmacist and Community Surveillance for Adverse Drug Reactions
- 30.10 Pharmacy Practice in the ED: Pharmacotherapy Specialty
- 30.11 Summary and Conclusions
- References

Chapter 31: Pharmacy Case Law Review

Roger N. Morris, R.Ph., J.D., and William J. Stilling, R.Ph., M.S., J.D.

31.1 Administrative Law

A. Due Process—Pharmacist Licensure

1. Berjikian, et al. v. Franchise Tax Board et al., No. CV 13–06301 DDP, 2015 WL 1185472 (C.D. Cal. March 12, 2015)

31.2 Antitrust

A. State Regulatory Boards Immunity

1. North Carolina Bd. of Dental Examiners. v. Federal Trade Commission, 135 S. Ct. 1101 (Feb. 25, 2015)

31.3 Civil Procedure

A. Spoliation of evidence—Pharmacy’s Duty to Maintain Evidence of Misfill

1. Burton v. Walgreen Co., 2015 WL 4228854 (D. Nev. July 10, 2015)

31.4 Conscientious Objection

A. Emergency Contraception

1. Stormans, Inc. v. Wiesman, 794 F.3d 1064 (9th Cir. 2015)

31.5 Controlled Substances

A. Duty to Verify DEA Registration

1. Farmacia, Yani, 80 Fed. Reg. 29,053 (May 20, 2015)
2. JM Pharmacy Group Inc., d/b/a/ Farmacia Nueva and Best Pharma Corp., 80 Fed. Reg. 28,667 (May 19, 2015)

B. Constitutionality

1. *McFadden v. United States*, 135 S. Ct. 2298 (June 18, 2015)

31.6 Criminal

A. Violations of Pharmacy Law Applied to Non-pharmacists

1. *Moore v. State of Florida*, NO. 1D14-3527, 2015 WL 4464689 (Fla. Dist. Ct. App. July 21, 2015), reh'g denied (Sept. 1, 2015)

B. PMP Records

1. *Lundy v. State*, 26 N.E.3d 656 (Ind. Ct. App. Feb. 20, 2015)

C. Second Degree Murder

1. *U.S. v. Barry J. Cadden, et al.*, 2014 WL 7151586 (D. Mass. Dec. 16, 2014)

31.7 Defamation

A. Physician against Pharmacist

1. *LeFrock v. Walgreen Co.*, 77 F. Supp.3d 1199 (M.D. Fla. Jan. 16, 2015)

B. Duty to Fill

1. *Kadambi v. Express Scripts*, 2015 WL 475373 (N.D. Ind. February 5, 2015)

31.8 Employment

A. Discrimination (Pregnancy)

1. *Torres-Skair v. Medco Health Solutions, Inc.*, 595 F.App'x 847 (11th Cir. Dec., 4, 2014)

B. Employment at Will

1. *Hoven v. Walgreen Co.*, 751 F.3d 778 (6th Cir. June 2, 2014)

C. Americans with Disability Act

1. *Stevens v. Rite Aid Corp., et al.*, 6:13-cv-00783 (N.D.N.Y., September 23, 2015)

D. Overtime Class Action

1. *Baugh v. CVS Health, et al.*, 2:15-cv-00014 (E.D. Penn., July 27, 2015)

E. Medical Marijuana

1. *Coats v. Dish Network*, 350 P. 3d, 849 (Colo. June 15, 2015)

31.9 Fraud and Abuse

F. False Claims

1. *United States v. Express Scripts, Inc.*, 602 F. App'x 880 (3rd. Cir. Feb. 20, 2015)

G. False Claims—Generic Substitutions

1. Doe v. Houchens Indus., Inc., No. 1:13-CV-00196-RLY, 2015 WL 133706 (S.D. Ind. Jan. 9, 2015)

H. False Claims & Anti-Kickback Statute

1. U.S. ex rel. Kester v. Novartis Pharm. Corp., No. 11 CIV. 8196 CM, 2015WL 1650767 (S.D.N.Y. Apr. 10, 2015)

I. Consumer Fraud

1. City of Chicago v. Purdue Pharma L.P., 2015 WL 2208423 (N.D. Ill. May 8, 2015)

31.10 Negligence

A. Duty to Provide Medication

1. Davies v. Virginia CVS Pharmacy, LLC, et al., 7:14-CV-00175, 2014 WL 6460787 (W.D. Va. Nov. 17, 2014)

B. Duty Not to Dispense

1. Oleckna v. Daytona Disc. Pharmacy, 162 So. 3d 178 (Fla. Dist. Ct. App. 2015)

31.11 Privacy

C. Patient Privacy–Vicarious Liability

1. Walgreen Co. v. Hinchy, 25 N.E.3d 748 (Ind. Ct. App. Jn. 15, 2015) reh'g of, 21 N.E.3d 99 (Ind. Ct. App. Nov. 14, 2014)

D. Text Messages

1. Thompson v. CVS Pharmacy, Inc., 6:204-cv-02081 (M.D. Fla. Dec. 19, 2014)

E. Robocalls

1. Kolinek v. Walgreen Co., 2014 WL 3056813, (N.D. Ill. July 7, 2014)

31.12 Product liability

A. Learned Intermediary Doctrine

1. Watts v. Medicis Pharm. Corp., 342 P.3d 847 (Ct. App. 2015), review granted in part (Sept. 22, 2015)

B. Product Liability (applicability to pharmacists)

1. Randol Mill Pharmacy v. Miller, 465 S.W.3d 612 (Tex. 2015), reh'g denied (Sept. 11, 2015)

Willis C. Triplett, Pharm.D.

32.1 Introduction

32.2 Compounding Trends and Driving Forces

32.3 Optimizing the Regulatory Balance Between “Manufacturing” versus “Compounding”

32.4 Investigations, Indictments, Convictions, and Acquittals after the Fungal Meningitis Outbreak

32.5 Memorandum of Understanding (MOU)

32.6 U SP, NABP, and the State Pharmacy Regulatory Authorities

32.7 Physician and Medical Office Compounding

32.8 Compounding “Center of Excellence” (“COE”) and the Quality Assurance Paradigm Shift

32.9 Conclusions and Forecasts Regarding Patient Injury from Healthcare Compounding

32.10 Recommended Readings

CHAPTER 33: Compounding Pharmacy Fraud and Unethical Practices

James T. O'Donnell, Pharm.D., M.S., FCP

33.1 Introduction

33.2 Criminal Prosecutions of Pharmacy Compounders

33.3 Over-Prescribing and Over-Charging of Compounded Drugs

A. Department of Justice News Releases

B. News Reports in Newspapers

33.4 Not Yet Criminal? Insurance Companies Fighting Back

A. No-Fault Pain Compounded and Topical Pain Product

B. Report Challenging the Pricing and Efficacy of a Compounded Pain Cream Prescription

C. Ingredients and Costs of Pain Cream

33.5 General Discussion – Compounded Pain Topical Creams

A. Evidence of Efficacy?

B. Expensive Ingredients

33.6 Ingredients Review of Efficacy and Mechanism of Action

A. Diclofenac

B. Menthol (Methyl Salicylate)

C. Lidocaine

1. Lidocaine Topical Toxicity

D. Amitriptyline

E. Cyclobenzaprine

F. Dimethylsulfoxide (DMSO)

33.7 Global Opinions for the Prescription CPTM formula 8-NC Claim Challenge

33.8 Discussion and Further Bases of Opinions

33.9 Overbilling of Topical Diclofenac Gels, Lidocaine Creams and Ointments and Patches

A. Diclofenac 3" (Solaraze)

B. Lidocaine Topical Commercial Products

33.10 Recommendations

33.11 Summary and Conclusions

References

Part IV: FORENSIC AND TOXICOLOGY ISSUES

Chapters 34 – 42

Chapter 34: Alcohol

James T. O'Donnell, Pharm.D., M.S., FCP and James J. O'Donnell III, M.S., Ph.D.

34.1 Introduction

34.2 Alcohol Injury Epidemiology

34.3 Alcohol Intoxication Effects in Litigation

34.4 Differences between Civil litigation involving alcohol from Criminal/DUI

34.5 Settings for Alcohol Related Civil Litigation

A. Employment

34.6 Police Activities

- A. Police Pursuit
- B. Excessive Police Force
- C. Alcohol Effects on Aggression and Judgment

34.7 Motor Vehicle Collisions

- A. Vehicle/Vehicle
- B. Motorcycle Cases
- C. Boating
- D. Vehicle/ Pedestrian

34.8 Alcohol and Falls

- A. Stairs - no alcohol test - fall down bar stairs
- B. Stairs - Residential Stairs Fall -Adjustment of Calculated BAC due to Morbid Obesity
- C. Tripped on Threshold – Sued Condominium Association

34.9 Dram Shop (Bar Liability for Serving Intoxicated Persons)

34.10 Biomarkers for Alcohol

- A. Family Law
- B. False Positive Alcohol Biomarkers in Diabetes

34.11 Miscellaneous Topics Reports

- A. Retrograde Extrapolation (See also legal cases Floyd and Cuellar earlier in this chapter.)
- B. Appellate Court reverses Trial Court Barring of BAC

34.13 Summary and Conclusions

References

Chapter 35: Cocaine

James C Norris, Ph.D., D.A.B.T and Rodney G Richmond, R.Ph., MS, CGP, FASCP, FACFE

35.1 Historical Background

35.2 Medical Usages of Cocaine

35.3 Illegal Usage of Cocaine

35.4 Routes of Administration

35.5 Effects of Cocaine

35.6 Psychotic Disorders Induced by Cocaine

35.7 Addiction

35.8 Cognitive Deficits

35.9 Prenatal Cocaine Exposure (PCE)

35.10 Violence

35.11 Tolerance

35.12 Withdrawal or Abstinence Effects

35.13 Mechanisms of Action

35.14 Metabolism

35.15 Blood Levels

35.16 Urine Levels

35.17 Impairment

35.18 Associated Deaths with Cocaine Usage

35.19 Summary and Conclusions

References

Chapter 36: Marijuana: Pharmacology, Toxicology and Forensic Issues

Stephanie E. Tedford, Ph.D., James T. O'Donnell PharmD, MS, FCP, and James J. O'Donnell III MS, Ph.D.

36.1 Introduction

36.2 Federal Law vs. State Law

A. Harrison Narcotics Tax Act

B. Comprehensive Drug Abuse Control and Prevention Act

C. Marijuana Drug Laws at the State Level

D. Legalization

E. Decriminalization

F. Marijuana Policy Project

36.3 Controlled Prescription and Distribution of Medical Marijuana

A. Medical Conditions Approved for Treatment with Medical Marijuana

B. Marijuana and Epilepsy

C. Marijuana and Endometriosis

36.4 Pharmacological Properties of Marijuana

A. Active Compounds and Overview of Pharmacology

B. Variability in Marijuana Regulation and Content Uniformity

C. Routes of Administration

D. Pharmacokinetics – Time Course of THC and Metabolites

E. Pharmacodynamics

F. Vaping vs. Traditional Smoking of Cannabinoids

G. Traditional Smoking vs. Ingestion of Cannabinoids

H. Pharmacokinetics Applications: Timing of the Peak Euphoric Effect

I. Bioavailability

1. Is There a Good Model for Marijuana Ingestion?

2. Overall Advantages of the Oromucosal Route?

3. Can the Effects After Ingestion of Marijuana be Made More Objective?

36.5 Marijuana Safety

A. Serious Adverse Effects

B. Risk of Psychosis

1. Drug-induced Psychosis: Potential Mechanisms

2. Vaping and Associated Risk for Psychosis

C. Pulmonary Function

D. Risk of Addiction

E. Effect on Brain Development

F. Long Term Behavioral Effects

G. Age of Onset of Use

36.6 Impact of Legalization

A. Hospital Resources

B. Driving Under the Influence of Drugs

C. Relationship of Marijuana Use and Co-Use with other Substances

36.7 Analysis and Testing for Marijuana Use

36.8 Scientific Data Relating to THC

A. Blood THC vs. Brain THC: Any Relationships?

B. Relationships Between Percent Plant-THC and Plasma-THC

C. Is There a Relationship Between Percent THC in the Smoked Cigarette and Plasma THC?

D. Relation Between Degree of “High” and Plasma THC

E. Occasional Marijuana Users vs. Practiced Users

F. Is THC the Only Psychoactive Cannabinoid?

G. Urine Testing for Cannabinoids: Clinical or Evidentiary Value?

H. Impairment and Marijuana: Laboratory and On-Road Driving Performance Data

I. Hospital and Provider Considerations

36.9 Forensic Case Reports

36.10 Summary and Conclusions

References

Chapter 37: Drug Evaluation and Classification Program: An Evidence-Based Analysis

Fran M. Gengo Pharm.D., FCP and Anna Mattle, Pharm.D., M.S.

37.1 Introduction

37.2 The 12 Steps of DRE Examinations

37.3 Scientific Evaluation of DRE Examinations

A. Step 2: Interview of Arresting Officer

B. Step 3: Preliminary Examination and Initial Pulse Measurement

C. Step 4: Eye Examination

- D. Step 5: Divided Attention Tests
- E. Step 6: Second Pulse Reading, Body Temperature, and Blood Pressure Measurement
- F. Step 7: Eye Examination of Pupil Size in Various Lighting Conditions
- G. Step 8: Assessment of Muscle Tone
- H. Step 11: DRE Officer Opinion Statement
- I. Step 12: Toxicology Sample

37.4 Literature Evaluations And Critiques Of Dre

37.5 Cannabis

37.6 Statistical Validity and Overall Strength of DRE Studies

37.7 DRE Support Literature

A. Bigelow et al. 1985 Study

B. Heishman et al. 1996 and 1998 Studies

C. Smith et al. 2002 Study

D. Shinar and Schechtman 2005 Study

E. Specific Identification of Drug Class by DRE Officers in Validation Studies

37.9 Summary

37.10 Summary and Conclusions

References

Chapter 38: Involuntary Intoxication

James T. O'Donnell, Pharm.D., M.S., FCP, ABCP, FACN, James J. O'Donnell III, M.S., Ph.D., William Vaughn, J.D.

38.1 Introduction

38.2 Legal Defense Considerations for a Violent Crime

38.3 Confirming That Drugs are Involved in a Violent Crime

38.4 Beyond Pharmacology: The Multifactorial Role of Drugs in Aggression and Violence

38.5 Association of Drugs with Aggression and Violence

38.6 Mechanisms of Drug-Induced Violence

38.7 Intoxication of Victim Defense

38.8 Summary and Conclusions

References

Chapter 39: Drug-Induced Aggression and Violence

Peter D. Anderson, Pharm.D., BCPP

39.1 Classification of Aggression

39.2 Causes of Aggression and Violence

A. Neurobiology of Aggression

B. Medical and Psychiatric Causes of Aggression

39.3 The Role of Drugs as a Cause of Violence

A. Introduction

B. Problems with the Literature

C. Specific Drugs or Drug Classes that cause aggression

1. Ethanol

2. Lysergic Acid Diethylamide

3. Phencyclidine and Ketamine

4. Anabolic Steroids

5. Insulin

6. Psychostimulants

7. Benzodiazepines

8. Selective Serotonin Reuptake Inhibitors

9. Varenicline

10. Environmental Chemicals

39.4 The Drug-Induced Insanity Defense

39.5 Summary and Conclusions

References

Chapter 40: Forensic Drug Testing Chapter

James J. O'Donnell III, M.S., Ph.D, and James T. O'Donnell, Pharm.D., M.S., FCP, ABCP, FACN

40.1 Introduction

40.2 Non-Regulated Drug Testing

40.3 Regulated Drug Testing

40.4 Voluntary Programs

40.5 Establishment of a Workplace Program

A. Written Policy

B. Employee Assistance Programs

C. Employee Awareness Training

D. Supervisor Training

E. Drug Testing

40.6 The Drug-Testing Process

A. Specimen Collection

B. Accessioning

C. Drugs to Be Tested

D. Screening Tests

E. Confirmation Tests

F. Reporting and Storage of Samples

G. Prevention Against and Detection of Drug Test Cheating

40.7 Additional Program Aspects

A. The Medical Review Officer (MRO)

B. Public Interest Exclusions (PIE)

C. Blind Performance Testing

D. Alcohol Testing

40.8 Special Drug-Testing Issues

A. Type of Matrix

1. Hair Testing

2. Saliva Testing

3. Sweat Testing

4. Blood

5. Urine

B. Alternate Sources of Drug Exposure

C. Amphetamine Testing Issues

D. Medical Use of Drugs

40.9 Legal Aspects of Workplace Drug-Testing

A. Constitutional Issues

B. State and Federal Mandates

40.10 Discovery: The “Litigation Package”

40.11 Case Reports

40.12 Summary and Conclusions

References

Chapter 41: Postmortem Redistribution and Interpretation of Drug Levels

Gourang P. Patel Pharm.D., M.Sc., BCPS, BCCCP, FCCM

41.1 Abstract

41.2 Introduction

41.3 Review of a Case File

41.4 Postmortem Considerations

A. Physiologic Changes in the Body After Death

B. Drug Characteristics

41.5 Analysis of Drug Level Information

41.6 Summary and Conclusions

References

Chapter 42: Addiction as Mitigation

Barry D. Hargan, M.S., MHA and James T. O'Donnell, Pharm.D., M.S., FCP

42.1 Introduction

42.2 Clinical Variables Which Contribute to the Onset of Addiction

A. Genetic Predisposition

B. Learned Behavior

C. Psychopathological Exposure

42.3 Substance/Medication-Induced Mental Disorder

A. Executive Summary of Opinion

B. Neurotoxicity Mechanisms of Alcohol and Anabolic Steroids in the Developing Brain

C. Anabolic Steroid Effects on Brain Structure and Function

D. Translational Impact – what does this mean to a teenager abusing large amounts of alcohol and steroids?

E. Clinical and Practical Applications of the Basic Neuroscience

F. Behavioral Abnormalities Associated with Anabolic Steroid Use

G. Defendant's Alcohol and Anabolic Steroid Use

1. Alcohol

H. Expert Opinions Regarding Substance-Induced Brain Damage Affecting Behavior

42.4 The Simplified Version of Neurobiology and the Addicted Brain

42.5 Cocaine

42.6 Expert Testimony Concerning Addictive Disorders

A. Role of the Addictions Expert

B. Some Testimony Experiences and the Limits of Opinions

C. Preparation

42.7 Additional Considerations Concerning Addiction Mitigation

A. Neuropsychological Evaluation

42.8 Summary and Conclusions

References